Health care value screen
Query: US large-cap health care stocks with positive earnings growth, ranked by forward P/E, showing distance from 52-week high · data as of 2026-10-16
Screened US health care stocks with market cap ≥ $10B and positive YoY EPS growth (61 names matched), ranking by ascending forward P/E with a 45-row table (symbol, company, industry, market cap, forward & TTM P/E, EPS/revenue growth, % from 52W high, % above 150D SMA, 1M/3M/6M/1Y returns, relative volume, momentum potential) plus commentary, an interpretive narrative, and an industry-grouped heatmap sized by market cap with toggles on forward P/E and % from 52W high.
0 US large-cap (>= $10B) health care stocks show positive year-over-year EPS growth as of October 16, 2026. Valuation dispersion is wide: managed care and a few pharma names trade in the single digits to low-teens forward P/E, while biotech, tools and diagnostics names sit at 30x+ on recovery earnings.
US Large-Cap Health Care Stocks with Positive EPS Growth — Cheapest Forward P/E First
No table data
Health Care Large Caps by Industry — Size = Market Cap
[heatmap: Health Care Large Caps by Industry — Size = Market Cap]
0
Where the value sits in large-cap health care
Cheap forward multiples are not randomly distributed across this screen — they cluster in three places, each for a different reason:
1. Big pharma with a cliff in the future. Bristol-Myers, Sanofi, GSK, AstraZeneca, Novartis, Merck and Novo Nordisk all trade in the single digits to mid-teens on forward earnings. The market is not questioning the cash flows; it is discounting the duration of those cash flows ahead of major loss-of-exclusivity events, plus, for the European names, a persistent non-US listing discount. In a market where the cost of capital is repricing long-dated cash flows (see the widening spread between dividend payers and non-payers), these shorter-duration, cash-return-heavy franchises are the least exposed to that penalty.
2. Policy-exposed domestic care providers (FMS, UHS, CI, HCA). Hospital operators and managed care sit at 6–14x because reimbursement is a political variable, not a demand variable. Utilization is fine; Medicaid supplemental payments and PBM reform are what caps multiples. Cigna's additional discount for pharmaca-benefit exposure makes it the value anchor of the group.
3. Cyclical recovery stories (Solventum, Philips, Smith & Nephew, Teva). These look cheap on depressed-base comparisons and depend on self-help execution and margin repair rather than top-line growth.
Where the risk is concentrated
Earnings-growth figures in this screen are noisy at both tails. Tripled-thousand-percent growth for Incyte, Gilead and Vertex reflects low bases, one-time items and launch ramp, not durable growth rates. A forward P/E of 12x on a number that will not repeat is not a bargain. Conversely, Novo Nordisk's drawdown is the screen's most interesting contrarian valuation gap — the GLP-1 demand story is intact while pricing and supply worries have compressed the multiple.
Setup and momentum
Technical positioning splits the list cleanly. Names at or near 52-week highs (Teva, Exelixis, Gilead, Cardinal Health, McKesson, Encompass, TMO) carry the strongest momentum scores and reflect earnings revisions actually winning. The steepest drawdowns belong to quality-growth franchises (Boston Scientific, Zoetis, Alnylam, Novo Nordisk) — these are where a value screen meets a quality pullback, but none is a trade until the trend stabilizes. Health care as a sector has been one of the better performers of late, so the cheaper names here are not cheap because the sector is out of favor — they are idiosyncratically discounted.
Run a version of this yourself
Describe the idea in plain English and Relaxfolio returns a researchable shortlist with the charts, fundamentals, and risks attached.
Educational research tool — not investment advice. A screen is a starting point, not a recommendation.